By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Pacific Biosciences has gone public, raising $200 million through its initial public offering.

The Menlo Park, Calif.-based developer of single-molecule, real-time sequencing technology offered 12.5 million shares at $16 per share, the mid-point of its last estimated range of $15-$17. It expects to begin trading today on the Nasdaq under the ticker symbol "PACB."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genes under positive selection in Plasmodium falciparum populations, genetic variation in Epstein-Barr viruses, and more.

Cancer clinical trial patients settle with Anil Potti and Duke University.

A trio of researchers is trying to raise money to sequence and analyze the genome of a cat with a suite of unusual traits.

Two Johns Hopkins researchers discuss the need for evidence-based data analysis.